Logo

American Heart Association

  53
  0


Final ID:

Liver-specific Deletion of Carnitine Palmitoyltransferase 1a Lowers Apolipoprotein B Containing Lipoproteins in Mice

Abstract Body: Background: Genome- and epigenome-wide association studies have associated variants and methylation status of carnitine palmitoyltransferase 1a (CPT1a) to reductions in very low-density lipoprotein (VLDL) cholesterol and triglyceride levels. The primary goal of this project is to determine the mechanism by which CPT1a alters hepatic and lipoprotein metabolism.

Methods: Eight-week-old Cpt1a floxed mice expressing the human APOB100 transgene (Cpt1afl/fl/B100Tg) were administered control adenoassociated virus (AAV) or AAV encoding Cre-recombinase under control of a liver specific promoter (TBG-Cre). Control and LKO mice were placed on low-fat control or western-type diet (WTD; 42% kcal fat, 0.2% cholesterol) for 16 weeks. Livers were collected and used for histological and lipid analysis, while gene and protein expression were measured by RNA sequencing (bulk, single cell) and immunoblotting, respectively. Lipoprotein composition in plasma was determined by size exclusion chromatography and nuclear magnetic resonance (NMR). Liquid and gas chromatography-mass spectrometry were employed to measure bile acid species and fecal neutral sterols, respectively.

Results: Mice with liver-specific deletion of Cpt1a (LKO) displayed lower circulating APOB levels consistent with reduced triglyceride rich lipoproteins and LDL particle number. No changes in bile flow rate, cholesterol secretion rate, bile acid secretion rate, total bile acids, or fecal cholesterol levels were observed in control or LKO mice. Despite a reduction in steady-state plasma lipids, VLDL-triglyceride secretion rates were enhanced in LKO mice, suggesting accelerated clearance of apoB-containing lipoproteins. In addition, western diet feeding elevated hepatic triglycerides in LKO mice across both sexes, while cholesterol (free and esterified) increased by ~2.5-fold specifically in females. Greater accumulation of free cholesterol coincided with an increase in inflammation and fibrosis of the liver in female LKO mice.

Conclusions: Liver-specific Cpt1a deletion reduces plasma LDL-cholesterol and triglycerides, despite having accelerated VLDL-secretion. Increases in hepatic free cholesterol levels were observed only in female LKO mice, which associates with a pro-inflammatory gene signature and fibrosis of the liver. These studies provide mechanistic insight into why genetic variants in Cpt1a associate with reductions in circulating apoB-containing lipoproteins in humans.
  • Helsley, Robert  ( University of Kentucky , Lexiton , Kentucky , United States )
  • Shalaurova, Irina  ( LabCorp, inc , Cary , North Carolina , United States )
  • Connelly, Margery  ( LABCORP , Morrisville , North Carolina , United States )
  • Saito, Kai  ( University of Kentucky , Lexiton , Kentucky , United States )
  • Morganti, Josh  ( University of Kentucky , Lexiton , Kentucky , United States )
  • Gordon, Scott  ( University of Kentucky , Lexiton , Kentucky , United States )
  • Graf, Gregory  ( UNIVERSITY KENTUCKY , Lexiton , Kentucky , United States )
  • Zelows, Mikala  ( University of Kentucky , Lexiton , Kentucky , United States )
  • Noffsinger, Victoria  ( UNIVERSITY KENTUCKY , Lexington , Kentucky , United States )
  • Anspach, Garrett  ( University of Kentucky College of P , Lexington , Kentucky , United States )
  • Dharanipragada, Nikitha  ( University of Kentucky , Lexiton , Kentucky , United States )
  • Mead, Anna  ( University of Kentucky , Lexiton , Kentucky , United States )
  • Cobo, Isidoro  ( University of Alabama at Birmingham , Birmingham , Alabama , United States )
  • Carter, Abby  ( University of Kentucky , Lexiton , Kentucky , United States )
  • Wu, Qinglin  ( LabCorp, inc , Cary , North Carolina , United States )
  • Author Disclosures:
    Robert Helsley: DO NOT have relevant financial relationships | Irina Shalaurova: No Answer | Margery Connelly: DO have relevant financial relationships ; Employee:Labcorp:Active (exists now) ; Individual Stocks/Stock Options:Labcorp:Active (exists now) | Kai Saito: No Answer | Josh Morganti: No Answer | Scott Gordon: DO NOT have relevant financial relationships | Gregory Graf: No Answer | Mikala Zelows: No Answer | Victoria Noffsinger: No Answer | Garrett Anspach: No Answer | Nikitha Dharanipragada: DO NOT have relevant financial relationships | Anna Mead: No Answer | Isidoro Cobo: No Answer | Abby Carter: No Answer | Qinglin Wu: No Answer
More abstracts on this topic:
ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

Adherence to Lipid Lowering Therapy among US Veterans with Atherosclerotic Cardiovascular Disease

Ward Rachel, Gaziano Michael, Wellman Helen, Yel Nedim, Young Melissa, Coleman-lopez Mason, Niu Xiaoli, Mcelligott Sean, Gagnon David, Djousse Luc

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available